The introduction of CDK4/6 inhibitors into the treatment of HR-positive, HER2-negative metastatic breast cancer (mBC) resulted in a paradigm shift, and these agents are now considered the gold standard for first-line treatment. Since their approval, robust real-world data have been collected on the safety and efficacy of these agents outside the confines of a clinical trial. This includes new information on optimal selection between CDK4/6 inhibitors based on patient and disease characteristics and how best to sequence treatments across multiple lines of therapy.
This activity, CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer, will provide oncology practitioners with up-to-date information on the use of CDK4/6 inhibitors in the treatment of patients with HR-positive, HER2-negative mBC, including an in-depth evaluation of current clinical trial data and real-world experience with available CDK4/6 inhibitors and strategies for developing personalized patient treatment plans that take into consideration patient and disease characteristics such as comorbidities, menopausal status, and site of metastasis.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
Advances in Cancer Screening and Detection: What PCPs Need to Know
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.